The effects of some neuroleptics and d-amphetamine on striatal 2-phenylethylamine in the mouse. 1991

A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
Department of Psychiatry, University of Saskatchewan, Saskatoon, Canada.

1. Mouse striatal 2-phenylethylamine was not changed at 2 hr following the administration of chlorpromazine, fluphenazine or spiperone. 2. In contrast, when the mice were first given pargyline (2 mg kg-1), treated with chlorpromazine, fluphenazine or spiperone 2 hr later and killed at 4 hr, a significant increase (to 130-170%) in the accumulation of 2-phenylethylamine was observed with respect to the pargyline controls. 3. The effect of chlorpromazine was consistently observed after pretreatment with either deprenyl (2 mg kg -1) or high doses (200 mg kg-1) of pargyline that produced different degrees of MAO inhibition. 4. Following pretreatment with pargyline (2 mg kg-1), d-amphetamine (5 mg kg-1) produced a significant reduction in striatal 2-phenylethylamine concentrations (to 39% of pargyline-treated controls). 5. The findings show that inhibition of dopamine transmission by neuroleptics increases the rate of 2-phenylethylamine accumulation. 6. Conversely, a stimulation of dopamine transmission by d-amphetamine results in a reduction in the rate of accumulation of 2-phenylethylamine and supports the concept of 2-phenylethylamine may be a neuromodulator of dopamine transmission.

UI MeSH Term Description Entries
D008297 Male Males
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D003913 Dextroamphetamine The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. d-Amphetamine,Curban,Dexamfetamine,Dexamphetamine,Dexedrine,Dextro-Amphetamine Sulfate,DextroStat,Dextroamphetamine Sulfate,Oxydess,d-Amphetamine Sulfate,dextro-Amphetamine,Dextro Amphetamine Sulfate,Sulfate, Dextroamphetamine,d Amphetamine,d Amphetamine Sulfate,dextro Amphetamine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine

Related Publications

A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
April 1977, Brain research,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
June 1974, Brain research,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
October 1983, The Journal of pharmacology and experimental therapeutics,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
November 1974, Life sciences,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
October 1979, Pharmacology, biochemistry, and behavior,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
October 1986, Neuropharmacology,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
January 1983, The International journal of neuroscience,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
November 1983, European journal of pharmacology,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
January 1979, Neuropharmacology,
A V Juorio, and A J Greenshaw, and M Y Zhu, and I A Paterson
January 1993, Neuroscience and biobehavioral reviews,
Copied contents to your clipboard!